The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Well let’s agree to disagree! I personally think it’ll be much sooner especially now with the bod wanting to prove a point! Plus if lost/found data by kissie is true! I’m looking forward to the FY results and hope the bod will give us an update on nxp004 and possibly the NXP002 Japanese deal!
Randomchancer - I’d rather be a ramper than a deramper like you!
Love your post about probably won’t get a decent RNS until Christmas! And then saying best to sell! That’s pure solid gold!
Soupdragon78
I’m surprised by your change in tact lately you still holding the 1.6mil?? :)
What i find interesting is your failure to understand the words ‘proving tech’ securing ‘IP’ ‘reforming a known drug’
I think you perhaps have alter motives currently and thats because you are guessing on the Labs not doing commercial works but thats your choice.
So for Nuformix to pass its first drug to clear all the way to market using its tech proves the value. Changing the format of delivery by cleverly altering its properties and then delivering it to fit the bio equivalent % was very good indeed.
It highlights why changing Tranalist on NXP002 being altered so now its in a format for inhalation is exactly what we are excited about.
https://www.ipwatchdog.com/2014/10/19/the-high-cost-of-making-pharmaceuticals/id=51737/
Soupdragon78- it’s clear what ever I post positive about NFX you’ll have an excuse to rip my post apart which is why I’d rather keep my knowledge to myself!
Or either in or out and it’s clear what your agenda is
SD78 - Let me explain why 2p prior to Ebers 51 million deal of ongoing payments and milestones.
The FACT NFX Passed CINV NXP001 drug last year something 95% of pharmaceutical companies fail on.
NFX passed it first time proving the technology.
They secured more patents and potential on NXP002 with a major deal potentially just around the corner.
They now have 100% world rights again on NXP001 with it being passed. Therefore its worth many millions more with a potential deal coming.
With other leads and news brewing on the major potential on NXP002 and NXP004 its clearly asset rich and moved a long long way from those levels.
So lets wait and see but I know what value is coming here soon
I'm happy to increase my holding along the way
This reminds me of last year before it moved from 2.5p to 14.8p. Just saying ..... fun reading everyone’s post!
A lot of you guys are so far off the mark It’s embarrassing to read. Funny though.
Patience will pay off here.
Good luck to all especially the lth who have been through this before
Seems quite a few people are getting restless! I know it’s frustrating but loads of info was stated in the last company update RNS
NXP004 - Initial data received is very promising and suggests NXP004 has a significantly superior anti-fibrotic action compared to currently approved therapies. The pilot study is expected to complete in the coming weeks and the Company will update shareholders once the resulting data has been considered.
Ebers - We are pleased to confirm that as a result of on-going development activities under the previously announced strategic cannabinoid agreement with Ebers Tech, a further patent filing has been made in relation to novel cannabinoid cocrystals. This latest patent filing triggers an undisclosed development milestone payment. Further cannabinoids have been added to the agreement, triggering additional undisclosed milestones and remain under development, with the potential for further milestone payments to Nuformix in the near-term.
NXP002 – Remember the negotiations are still ongoing which is a good thing right! Chris and the team will want the best deal for NFX and shareholders and the Japanese know how important this is to them, even moreso with problem from Covid-19 fibrosis coming to light..
I’m more than happy to sit tight and wait, we are in Q3 now so getting closer in my view. gla